Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells

Zhongliang Jiang, Nicole M. Fletcher, Rouba Ali-Fehmi, Michael Peter Diamond, Husam M. Abu-Soud, Adnan R. Munkarah, Ghassan M. Saed

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: Epithelial ovarian cancer (EOC) cells are known to be resistant to apoptosis through a mechanism that may involve alteration in their redox balance. NADPH oxidase is a major source of intracellular superoxide, which is converted to the less toxic product by superoxide dismutase (SOD). Superoxide contributes to hypoxia inducible factor (HIF)-1α stabilization. We sought to determine the effects of inhibiting the generation of intracellular reactive oxygen species (ROS) on apoptosis of EOC cells. Methods: Diphenyleneiodonium (DPI), an irreversible ROS inhibitor, was used to inhibit the generation of ROS in EOC cell lines, SKOV-3 and MDAH-2774, followed by assessment of apoptosis, NADPH oxidase, SOD3 and HIF-1α expression. A combination of immunohistochemistry, immunoprecipitation/western blot, and real-time RT-PCR were utilized to evaluate the expression of these enzymes in EOC cells as well as normal ovarian tissue and ovarian cancer tissue specimens. Results: DPI treatment significantly induced apoptosis in both EOC cell lines as evident by increased caspase-3 activity and TUNEL assay. Additionally, both EOC cell lines were found to express NADPH oxidase, HIF-1α, and SOD3, which were highly sensitive to DPI treatment. DPI treatment resulted in reduced NADPH oxidase, SOD3 and HIF-1α levels. Furthermore, ovarian cancer tissues were found to manifest higher NADPH oxidase levels as compared to normal ovarian tissues. Conclusions: These data suggest that lowering oxidative stress, possibly through the inhibition of NADPH oxidase, induces apoptosis in ovarian cancer cells and may serve as a potential target for cancer therapy.

Original languageEnglish (US)
Pages (from-to)418-423
Number of pages6
JournalGynecologic Oncology
Volume122
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

NADPH Oxidase
Oxidation-Reduction
Hypoxia-Inducible Factor 1
Apoptosis
Ovarian Neoplasms
Reactive Oxygen Species
Cell Line
Superoxides
Cohort Effect
Poisons
In Situ Nick-End Labeling
Therapeutics
Immunoprecipitation
Caspase 3
Superoxide Dismutase
Ovarian epithelial cancer
Real-Time Polymerase Chain Reaction
Oxidative Stress
Western Blotting
Immunohistochemistry

Keywords

  • Diphenyleneiodonium
  • Epithelial ovarian cancer
  • Hypoxia inducible factor-1 alpha
  • NADPH oxidase
  • Oxidative stress
  • Superoxide dismutase

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Jiang, Z., Fletcher, N. M., Ali-Fehmi, R., Diamond, M. P., Abu-Soud, H. M., Munkarah, A. R., & Saed, G. M. (2011). Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecologic Oncology, 122(2), 418-423. https://doi.org/10.1016/j.ygyno.2011.04.051

Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. / Jiang, Zhongliang; Fletcher, Nicole M.; Ali-Fehmi, Rouba; Diamond, Michael Peter; Abu-Soud, Husam M.; Munkarah, Adnan R.; Saed, Ghassan M.

In: Gynecologic Oncology, Vol. 122, No. 2, 01.08.2011, p. 418-423.

Research output: Contribution to journalArticle

Jiang, Z, Fletcher, NM, Ali-Fehmi, R, Diamond, MP, Abu-Soud, HM, Munkarah, AR & Saed, GM 2011, 'Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells', Gynecologic Oncology, vol. 122, no. 2, pp. 418-423. https://doi.org/10.1016/j.ygyno.2011.04.051
Jiang, Zhongliang ; Fletcher, Nicole M. ; Ali-Fehmi, Rouba ; Diamond, Michael Peter ; Abu-Soud, Husam M. ; Munkarah, Adnan R. ; Saed, Ghassan M. / Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. In: Gynecologic Oncology. 2011 ; Vol. 122, No. 2. pp. 418-423.
@article{2e96b43ef7ca428b89a27a90606bbf5c,
title = "Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells",
abstract = "Objective: Epithelial ovarian cancer (EOC) cells are known to be resistant to apoptosis through a mechanism that may involve alteration in their redox balance. NADPH oxidase is a major source of intracellular superoxide, which is converted to the less toxic product by superoxide dismutase (SOD). Superoxide contributes to hypoxia inducible factor (HIF)-1α stabilization. We sought to determine the effects of inhibiting the generation of intracellular reactive oxygen species (ROS) on apoptosis of EOC cells. Methods: Diphenyleneiodonium (DPI), an irreversible ROS inhibitor, was used to inhibit the generation of ROS in EOC cell lines, SKOV-3 and MDAH-2774, followed by assessment of apoptosis, NADPH oxidase, SOD3 and HIF-1α expression. A combination of immunohistochemistry, immunoprecipitation/western blot, and real-time RT-PCR were utilized to evaluate the expression of these enzymes in EOC cells as well as normal ovarian tissue and ovarian cancer tissue specimens. Results: DPI treatment significantly induced apoptosis in both EOC cell lines as evident by increased caspase-3 activity and TUNEL assay. Additionally, both EOC cell lines were found to express NADPH oxidase, HIF-1α, and SOD3, which were highly sensitive to DPI treatment. DPI treatment resulted in reduced NADPH oxidase, SOD3 and HIF-1α levels. Furthermore, ovarian cancer tissues were found to manifest higher NADPH oxidase levels as compared to normal ovarian tissues. Conclusions: These data suggest that lowering oxidative stress, possibly through the inhibition of NADPH oxidase, induces apoptosis in ovarian cancer cells and may serve as a potential target for cancer therapy.",
keywords = "Diphenyleneiodonium, Epithelial ovarian cancer, Hypoxia inducible factor-1 alpha, NADPH oxidase, Oxidative stress, Superoxide dismutase",
author = "Zhongliang Jiang and Fletcher, {Nicole M.} and Rouba Ali-Fehmi and Diamond, {Michael Peter} and Abu-Soud, {Husam M.} and Munkarah, {Adnan R.} and Saed, {Ghassan M.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2011.04.051",
language = "English (US)",
volume = "122",
pages = "418--423",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells

AU - Jiang, Zhongliang

AU - Fletcher, Nicole M.

AU - Ali-Fehmi, Rouba

AU - Diamond, Michael Peter

AU - Abu-Soud, Husam M.

AU - Munkarah, Adnan R.

AU - Saed, Ghassan M.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objective: Epithelial ovarian cancer (EOC) cells are known to be resistant to apoptosis through a mechanism that may involve alteration in their redox balance. NADPH oxidase is a major source of intracellular superoxide, which is converted to the less toxic product by superoxide dismutase (SOD). Superoxide contributes to hypoxia inducible factor (HIF)-1α stabilization. We sought to determine the effects of inhibiting the generation of intracellular reactive oxygen species (ROS) on apoptosis of EOC cells. Methods: Diphenyleneiodonium (DPI), an irreversible ROS inhibitor, was used to inhibit the generation of ROS in EOC cell lines, SKOV-3 and MDAH-2774, followed by assessment of apoptosis, NADPH oxidase, SOD3 and HIF-1α expression. A combination of immunohistochemistry, immunoprecipitation/western blot, and real-time RT-PCR were utilized to evaluate the expression of these enzymes in EOC cells as well as normal ovarian tissue and ovarian cancer tissue specimens. Results: DPI treatment significantly induced apoptosis in both EOC cell lines as evident by increased caspase-3 activity and TUNEL assay. Additionally, both EOC cell lines were found to express NADPH oxidase, HIF-1α, and SOD3, which were highly sensitive to DPI treatment. DPI treatment resulted in reduced NADPH oxidase, SOD3 and HIF-1α levels. Furthermore, ovarian cancer tissues were found to manifest higher NADPH oxidase levels as compared to normal ovarian tissues. Conclusions: These data suggest that lowering oxidative stress, possibly through the inhibition of NADPH oxidase, induces apoptosis in ovarian cancer cells and may serve as a potential target for cancer therapy.

AB - Objective: Epithelial ovarian cancer (EOC) cells are known to be resistant to apoptosis through a mechanism that may involve alteration in their redox balance. NADPH oxidase is a major source of intracellular superoxide, which is converted to the less toxic product by superoxide dismutase (SOD). Superoxide contributes to hypoxia inducible factor (HIF)-1α stabilization. We sought to determine the effects of inhibiting the generation of intracellular reactive oxygen species (ROS) on apoptosis of EOC cells. Methods: Diphenyleneiodonium (DPI), an irreversible ROS inhibitor, was used to inhibit the generation of ROS in EOC cell lines, SKOV-3 and MDAH-2774, followed by assessment of apoptosis, NADPH oxidase, SOD3 and HIF-1α expression. A combination of immunohistochemistry, immunoprecipitation/western blot, and real-time RT-PCR were utilized to evaluate the expression of these enzymes in EOC cells as well as normal ovarian tissue and ovarian cancer tissue specimens. Results: DPI treatment significantly induced apoptosis in both EOC cell lines as evident by increased caspase-3 activity and TUNEL assay. Additionally, both EOC cell lines were found to express NADPH oxidase, HIF-1α, and SOD3, which were highly sensitive to DPI treatment. DPI treatment resulted in reduced NADPH oxidase, SOD3 and HIF-1α levels. Furthermore, ovarian cancer tissues were found to manifest higher NADPH oxidase levels as compared to normal ovarian tissues. Conclusions: These data suggest that lowering oxidative stress, possibly through the inhibition of NADPH oxidase, induces apoptosis in ovarian cancer cells and may serve as a potential target for cancer therapy.

KW - Diphenyleneiodonium

KW - Epithelial ovarian cancer

KW - Hypoxia inducible factor-1 alpha

KW - NADPH oxidase

KW - Oxidative stress

KW - Superoxide dismutase

UR - http://www.scopus.com/inward/record.url?scp=79960446246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960446246&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.04.051

DO - 10.1016/j.ygyno.2011.04.051

M3 - Article

VL - 122

SP - 418

EP - 423

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -